Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Lo, S. Fan, Chi-leung Liu, Ching‐lung Lai, J. Wong (2003)
Prophylaxis and treatment of recurrent hepatitis B after liver transplantationTransplantation, 75
R. Wolfe, R. Webb, D. Dickinson, V. Ashby, Dawn Dykstra, T. Hulbert-Shearon, K. McCullough (2003)
Analytical approaches for transplant researchAmerican Journal of Transplantation, 3
M. Prieto, M. Berenguer, J. Rayón, J. Córdoba, L. Argüello, D. Carrasco, A. García-Herola, V. Olaso, M. Juan, M. Gobernado, J. Mir, J. Berenguer (1999)
High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodesHepatology, 29
E. Gane, B. Portmann, N. Naoumov, Heather Smith, J. Underhill, P. Donaldson, G. Maertens, Roger Williams (1996)
Long-term outcome of hepatitis C infection after liver transplantation.The New England journal of medicine, 334 13
R. Busuttil, Koichi Tanaka (2003)
The utility of marginal donors in liver transplantationLiver Transplantation, 9
S. Brillanti, M. Vivarelli, N. Ruvo, Ardo Aden, V. Camaggi, A. d’Errico, G. Furlini, R. Bellusci, E. Roda, A. Cavallari (2002)
Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantationLiver Transplantation, 8
Lake (2004)
Efficacy of triple therapy with mycophenolate mofetil (MMF), tacrolimus (tacro), and corticosteroids (CS) compared to tacro and CS immunosuppression inliver transplantation: an analysis of the US liver transplant experience (abstract).Am J Transplant, 4
M. Russo, J. Galanko, S. Zacks, K. Beavers, Michael and, R. Shrestha (2004)
Impact of Donor Age and Year of Transplant on Graft Survival in Liver Transplant Recipients with Chronic Hepatitis CAmerican Journal of Transplantation, 4
D. Dickinson, M. Ellison, R. Webb (2003)
Data sources and structureAmerican Journal of Transplantation, 3
R. Merion (2005)
Expanded criteria donors for kidney transplantation.Transplantation proceedings, 37 9
M. Wali, R. Harrison, P. Gow, D. Mutimer (2002)
Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis CGut, 51
H. Vargas, F. Dodson, J. Rakela (2002)
A concise update on the status of liver transplantation for hepatitis B virus: The challenges in 2002Liver Transplantation, 8
M. Berenguer, J. Crippin, R. Gish, N. Bass, A. Bostrom, G. Netto, J. Alonzo, R. Garcia‐Kennedy, J. Rayón, T. Wright (2003)
A model to predict severe HCV‐related disease following liver transplantationHepatology, 38
M. Charlton, E. Seaberg, R. Wiesner, J. Everhart, R. Zetterman, J. Lake, K. Detre, J. Hoofnagle (1998)
Predictors of patient and graft survival following liver transplantation for hepatitis CHepatology, 28
K. Burak, W. Kremers, K. Batts, R. Wiesner, C. Rosen, R. Razonable, C. Payá, M. Charlton (2002)
Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis CLiver Transplantation, 8
P. Sheiner, M. Schwartz, E. Mor, L. Schluger, Neil Theise, K. Kishikawa, V. Kolesnikov, H. Bodenheimer, S. Emre, C. Miller (1995)
Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantationHepatology, 21
H. Yoo, P. Thuluvath (2004)
Outcome of liver transplantation in adult recipients: Influence of neighborhood income, education, and insuranceLiver Transplantation, 10
M. Berenguer, M. Prieto, F. Juan, J. Rayón, F. Martínez, D. Carrasco, Á. Moya, F. Orbis, J. Mir, J. Berenguer (2002)
Contribution of donor age to the recent decrease in patient survival among HCV‐infected liver transplant recipientsHepatology, 36
V. Machicao, H. Bonatti, M. Krishna, B. Aqel, F. Lukens, J. Nguyen, B. Rosser, R. Satyanarayana, H. Grewal, W. Hewitt, D. Harnois, J. Crook, J. Steers, R. Dickson (2004)
Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C1Transplantation, 77
K. Chopra, A. Demetris, K. Blakolmer, I. Dvorchik, T. Laskus, Liangfu Wang, V. Araya, F. Dodson, J. Fung, J. Rakela, H. Vargas (2003)
Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantationTransplantation, 76
Edoardo Cervoni (1998)
Hepatitis CThe Lancet, 351
F. Villamil (2002)
Hepatitis B: Progress in the last 15 yearsLiver Transplantation, 8
S. Nair, J. Eustace, P. Thuluvath (2002)
Effect of race on outcome of orthotopic liver transplantation: a cohort studyThe Lancet, 359
R. Wiesner, M. Sorrell, F. Villamil (2003)
Report of the First International Liver Transplantation Society Expert Panel Consensus Conference on Liver Transplantation and Hepatitis CLiver Transplantation, 9
U. Neumann, T. Berg, M. Bahra, G. Puhl, O. Guckelberger, J. Langrehr, P. Neuhaus (2004)
Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-upTransplantation, 77
A. Zekry, P. Whiting, Darrell Crawford, P. Angus, G. Jeffrey, R. Padbury, E. Gane, G. McCaughan (2003)
Liver transplantation for HCV‐associated liver cirrhosis: Predictors of outcomes in a population with significant genotype 3 and 4 distributionLiver Transplantation, 9
J. Lake (2003)
The role of immunosuppression in recurrence of hepatitis CLiver Transplantation, 9
The variable impact of specific risk factors on survival outcomes based on pre‐transplantation diagnosis was analyzed in adult liver transplant recipients reported to the Scientific Registry of Transplant Recipients: 778 with hepatitis B (HBV), 3463 with hepatitis C (HCV) and 7429 without viral hepatitis. Graft and patient survival for the HBV and no viral hepatitis groups did not differ significantly. The HCV group had significantly lower graft (p = 0.0019) and patient survival (p < 0.0001) than the no viral hepatitis group. Patient survival was significantly lower (p = 0.0011) for HCV compared to HBV patients; differences in graft survival approached significance (p = 0.0561). Donor age, which was not a risk factor in patients with HBV, was the strongest predictor of graft loss and death in patients with HCV, starting with donors >40 years. Donor age >60 years was the strongest predictor of graft loss and death in patients without viral hepatitis. The risks of graft loss and death were reduced for patients on tacrolimus‐based immunosuppression with mycophenolate mofetil, regardless of disease etiology. There are clear differences in risk factors for poor outcomes based on underlying liver disease, particularly with regard to the impact of donor age.
American Journal of Transplantation – Wiley
Published: Mar 1, 2005
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.